[The place of lercanidipine in the treatment of cardiovascular diseases].
The data are presented on using the first, second and third generation calcium antagonists in cardio-vascular pathology patients. The accent has been made on the improved pharmacokinetic profile of the third generation calcium antagonists where modern preparation lerkanidipin belongs to. It is shown that lerkanidipine has expressed antihypertensive effect with no significant impact on the cardiac contraction frequency and its metabolic neutrality enables using the said preparation with diabetes mellitus and other metabolic disorders patients. Besides, an improved pharmacokinetic lerkanidine profile leads to organoprotective and antiaterogeneous effect. Significantly fewer side reactions as connected with activised simpatico-adrenal system, and peripheral edemas are observed as compared against other representatives of the said preparations category.